Device/Drug Borderline: Gray Areas Remain Despite New EU Guidance
Executive Summary
The regulation of products on the drug/device borderline has always been complex. New EU guidance aims to provide clarification, but some difficult and nuanced decision-making is still left to the manufacturer.